Ruffolo Robert R
SEC-identified person · CIK 1187308 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| LB Pharmaceuticals INC LBRX | Director | filed 2025–2026 |
| Elicio Therapeutics, Inc. ELTX | Director | filed 2023–2025 |
| Sigilon Therapeutics, Inc. SGTX | Director | filed 2020–2023 |
| Aridis Pharmaceuticals, Inc. ARDS] | Director | filed 2018–2022 |
| Stratus Media Group, Inc SMDID | Director | filed 2017–2018 |
| Wyeth WYE | Sr. VP & Pres., Wyeth Research | filed 2006–2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.